不同全球人群中镰状细胞贫血儿童羟基脲的药代动力学
该研究比较了来自美国、非洲和加勒比地区5项临床试验中451例镰状细胞贫血(SCA)儿童的羟基脲药代动力学(PK)参数。非洲儿童分布容积略低,但吸收速率和清除率相似。达到最大耐受剂量(MTD)的PK推荐剂量在美国(26.6 ± 5.9 mg/kg/天)、非洲(27.6 ± 6.5 mg/kg/天)和加勒比(25.2 ± 4.7 mg/kg/天)间有统计学差异但临床相似(P = .04)。基于美国儿童PK群体模型个体化给药可广泛用于其他全球人群。
要点
- 非洲儿童分布容积略低于美国儿童,但吸收速率和清除率相似。
- PK推荐达到MTD的剂量在美国、非洲和加勒比地区间有统计学差异(P = .04)但临床相似。
- 基于美国儿童PK群体模型个体化给药可广泛用于其他全球人群。
核心结论
- 不同全球人群中SCA儿童的羟基脲PK参数差异极小,预测达到MTD的剂量临床相似。
- 基于美国SCA儿童PK群体模型的个体化羟基脲给药可广泛用于其他全球人群。
研究设计与样本
- 比较5项临床试验(HUSTLE、TREAT、NOHARM、REACH、EXTEND)中451例SCA儿童的羟基脲PK参数。
- 使用经过验证的羟基脲PK软件程序HdxSim确定关键PK参数,并通过方差分析比较不同地区。
主要发现
- 共纳入451例SCA儿童,其中美国146例、非洲265例、加勒比地区40例。
- 非洲儿童分布容积略低,但吸收速率和清除率各地区相似。
- PK推荐达到MTD的剂量:美国26.6 ± 5.9 mg/kg/天,非洲27.6 ± 6.5 mg/kg/天,加勒比25.2 ± 4.7 mg/kg/天(P = .04)。
- 多变量回归中,较年轻年龄和网织红细胞计数升高与更高的PK推荐剂量相关。
关键数值与推荐
- PK推荐达到MTD的剂量在美国26.6 ± 5.9 mg/kg/天、非洲27.6 ± 6.5 mg/kg/天、加勒比25.2 ± 4.7 mg/kg/天间有统计学差异(P = .04)但临床相似。
- 较年轻年龄和网织红细胞计数升高与更高的PK推荐剂量相关。
临床怎么用
- 基于美国SCA儿童PK群体模型的个体化羟基脲给药可广泛用于其他全球人群以最大化该关键药物的获益。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hydroxyurea provides effective disease-modifying treatment for people with sickle cell anemia (SCA), especially when escalated to maximum tolerated dose (MTD), which has wide interpatient dosing variability due to pharmacokinetic (PK) differences. Whether hydroxyurea PK parameters differ among children with SCA in different global regions is unknown. We compared hydroxyurea PK parameters among children with SCA from 5 clinical trials: HUSTLE (United States), TREAT (United States), NOHARM (Uganda), REACH (Uganda and Kenya), and EXTEND (Jamaica). Key hydroxyurea PK parameters were determined using HdxSim, a validated hydroxyurea PK software program. The results were compared across regions by analysis of variance. PK profiles from 451 children with SCA (146 from the United States, 265 from Africa, and 40 from the Caribbean) were included. Children from Africa had slightly lower volumes of distribution, but absorption rate and clearance were similar across regions. The PK-recommended doses to achieve MTD were statistically different but clinically similar across the United States (26.6 ± 5.9 mg/kg per day), Africa (27.6 ± 6.5 mg/kg per day), and the Caribbean (25.2 ± 4.7 mg/kg per day) (P = .04). In multivariable regression, younger age and increased reticulocyte counts were associated with higher PK-recommended doses. Hydroxyurea PK parameters in children with SCA differ minimally across global populations, predicting clinically similar doses to achieve MTD. Individualized hydroxyurea dosing based on a PK-population model derived from US children with SCA can be used broadly to maximize the benefits of this critical medication in other global populations. These trials were registered at www.ClinicalTrials.gov as #NCT00305175 (HUSTLE), #NCT02286154 (TREAT), #NCT01976416 (NOHARM), #NCT01966731 (REACH), and #NCT02556099 (EXTEND).
引用
- Power-Hays A, McElhinney KE, Williams TN, et al. Hydroxyurea pharmacokinetics in children with sickle cell anemia across different global populations. Blood Adv. 2026. PMID: 41026975. doi:10.1182/bloodadvances.2025017254
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。